Get the Stockscreener App
5.86
1.21%
0.07
After Hours:
5.89
0.03
+0.51%
Candel Therapeutics Inc stock is traded at $5.86, with a volume of 443.38K.
It is up +1.21% in the last 24 hours and down -6.84% over the past month.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
See More
Previous Close:
$5.79
Open:
$5.81
24h Volume:
443.38K
Relative Volume:
0.54
Market Cap:
$321.69M
Revenue:
$124.00K
Net Income/Loss:
$-49.99M
P/E Ratio:
-3.4675
EPS:
-1.69
Net Cash Flow:
$-31.03M
1W Performance:
-1.68%
1M Performance:
-6.84%
6M Performance:
-34.71%
1Y Performance:
-13.19%
1-Day Range:
$5.76
$6.0395
1-Week Range:
$5.70
$6.16
52-Week Range:
$3.785
$14.60
Candel Therapeutics Inc Stock (CADL) Company Profile
Name
Candel Therapeutics Inc
Sector
Industry
Phone
617-916-5445
Address
117 KENDRICK STREET, NEEDHAM
Compare CADL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
5.86 | 317.84M | 124.00K | -49.99M | -31.03M | -1.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
401.00 | 100.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.90 | 61.55B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
447.00 | 58.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
706.41 | 43.59B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
332.04 | 33.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Resumed | H.C. Wainwright | Buy |
| Feb-20-25 | Initiated | Citigroup | Buy |
| Feb-19-25 | Initiated | Canaccord Genuity | Buy |
| Feb-07-25 | Initiated | BofA Securities | Buy |
| Dec-02-22 | Initiated | H.C. Wainwright | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Aug-23-21 | Initiated | Credit Suisse | Outperform |
| Aug-23-21 | Initiated | Jefferies | Buy |
| Aug-23-21 | Initiated | UBS | Buy |
View All
Candel Therapeutics Inc Stock (CADL) Latest News
How hedge fund analytics apply to Candel Therapeutics Inc. stockJuly 2025 Opening Moves & Consistent Income Trade Ideas - Newser
Candel Therapeutics shares rise 1.71% after-hours after appointing renowned immunotherapy expert Carl H. June to its Research Advisory Board. - AInvest
Is Candel Therapeutics Inc. forming bullish engulfing patternsJuly 2025 Macro Moves & AI Powered Market Entry Strategies - خودرو بانک
Price action breakdown for Candel Therapeutics Inc.Fed Meeting & Risk Managed Investment Strategies - Newser
Chart based analysis of Candel Therapeutics Inc. trendsJuly 2025 Trends & Precise Trade Entry Recommendations - Newser
Small Cap Stocks Gain Traction: MustGrow Biologics, Ocean Power Technologies, Medicus Pharma, Candel Therapeutics, Digi Power X, and G Mining Ventures Lead the Way - AInvest
Pattern recognition hints at Candel Therapeutics Inc. upsideTake Profit & Growth Focused Stock Pick Reports - Newser
Candel Therapeutics Inc. stock daily chart insightsMarket Activity Summary & Breakout Confirmation Alerts - Newser
Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board - The Manila Times
FDA-Approved CAR-T Pioneer Carl June Joins Candel Therapeutics to Guide Cancer Immunotherapy Development - Stock Titan
How high can Candel Therapeutics Inc. stock goQuarterly Portfolio Report & Target Return Focused Picks - Newser
Live market analysis of Candel Therapeutics Inc.July 2025 Selloffs & Weekly Watchlist for Consistent Profits - Newser
Will Candel Therapeutics Inc. face regulatory challengesJuly 2025 Short Interest & Stepwise Trade Execution Plans - خودرو بانک
Published on: 2025-09-02 07:27:55 - beatles.ru
Is Candel Therapeutics Inc. a play on infrastructure spendingJuly 2025 Breakouts & Real-Time Volume Spike Alerts - خودرو بانک
Is Candel Therapeutics Inc. stock entering bullish territory2025 Dividend Review & Technical Buy Zone Confirmation - Newser
Can Candel Therapeutics Inc. expand its profit margins2025 Investor Takeaways & Low Drawdown Momentum Trade Ideas - خودرو بانک
What does recent volatility data suggest for Candel Therapeutics Inc.Price Action & Growth Focused Investment Plans - Newser
Advanced analytics toolkit walkthrough for Candel Therapeutics Inc.2025 Trading Recap & Daily Entry Point Trade Alerts - Newser
Multi asset correlation models including Candel Therapeutics Inc.Market Growth Summary & Short-Term Trading Opportunity Alerts - Newser
How to track smart money flows in Candel Therapeutics Inc.July 2025 Action & Long-Term Growth Stock Strategies - Newser
Multi asset correlation models including Candel Therapeutics IncJuly 2025 Weekly Recap & Community Supported Trade Ideas - Newser
What indicators show strength in Candel Therapeutics Inc.Weekly Trend Report & Verified Technical Trade Signals - Newser
Using data models to predict Candel Therapeutics Inc. stock movementWatch List & Entry Point Confirmation Signals - Newser
Trend Dashboard Flags Candel Therapeutics Inc. As Potential Swing TradeJuly 2025 Movers & Long-Term Capital Growth Strategies - beatles.ru
Will Candel Therapeutics Inc. benefit from macro trendsJuly 2025 Short Interest & AI Optimized Trading Strategy Guides - Newser
What’s the recovery path for long term holders of Candel Therapeutics Inc. - Newser
Using flow based indicators on Candel Therapeutics Inc.July 2025 Gainers & Verified Technical Signals - Newser
How to use a screener to detect Candel Therapeutics Inc. breakoutsJuly 2025 Opening Moves & Daily Momentum Trading Reports - Newser
Can Candel Therapeutics Inc. be recession proofWeekly Stock Recap & Fast Gain Swing Trade Alerts - sundaytimes.kr
How institutional ownership impacts Candel Therapeutics Inc. stockJuly 2025 Earnings & Daily Risk Controlled Trade Plans - Newser
Candel Therapeutics Inc Stock (CADL) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):